Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Labour Government Would De-Link Innovation & Drug Pricing

The Current Drug Pricing System Would Be Totally Overhauled

Executive Summary

The Labour Party says it would overhaul the system for pricing medicines in the UK by de-linking innovation and price incentives if it gets into office at the next general election.

You may also be interested in...



UK Opposition Party Wants Compulsory Licenses For ‘Extortionate’ Medicines

The UK’s main opposition party says it would use compulsory licensing to ensure access to “extortionately” priced medicines. Unsurprisingly, the responses are polarized.

After Canada, Sweden Shows Interest In BeNeLuxA Joint Horizon Scanning

Dutch minister for medical care Bruno Bruins is hopeful that 10 countries will have joined the International Horizon Scanning Initiative when it kicks off in October.

European Parliament Signs Off Regulation To Tackle Medicine Shortages

The legislation will establish a new EU platform for monitoring and reporting medicines shortages.

Topics

UsernamePublicRestriction

Register

PS140910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel